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Among antifungal substances used in therapy,
azole compounds being imidazole and triazole
derivatives are the most important synthetic ones.
Due to high efficacy and acceptable safety profile
these compounds gained a strong position in therapy
(1-3). In this paper bifonazole, clotrimazole, econa-
zole, ketoconazole and miconazole as imidazole
derivatives and fluconazole and itraconazole as rep-
resentatives of triazole derivatives were analyzed.
So far, the compounds mentioned above were
determined using various techniques, exemplified
by chromatographic (4), biological (5) and electro-
analytical ones (6). However, there is a limited
amount of published papers related to UV spec-
trophotometry and derivative spectrophotometry. 
Bifonazole was determined directly (7, 8) and
by forming complex compound with indicator bro-
mophenol blue (9). For clotrimazole analyses were
performed after prior acidic hydrolysis (10), com-
plexation reaction (11, 12) or directly (8).
Econazole was analyzed directly (8, 13) and after
complexation (12). Fluconazole was also deter-
mined (14, 15), whereas for itraconazole no analy-
sis was reported till now. Ketoconazole determina-
tion included direct analyses (16-18) and complex-
es formation (12, 19-22). In case of miconazole
analyses were done indirectly with use of internal
standard (23), after complexation reaction (12) and
directly (8, 13, 24).
The above listing of publications illustrates
continuous demand for new research studies related
to commonly available spectrophotometrical tech-
nique within the group of antifungal azole medi-
cines. At first place, there is a need for direct analy-
ses. Because of possibility of derivatization of zero-
order absorption spectra by computer programmes,
enabling valuable analytical operations, there is a
need to use more accurate and sensitive derivative
spectrophotometry. 
The aim of this paper was to establish the con-
ditions for quantitative determination of analyzed
compounds for routine pharmaceutical analysis and
define essential parameters helpful in identification.
Moreover, analysis of several compounds from the
same azole group under uniform conditions enables
a comparison of variability of analytical parameters
depending on differences in their chemical struc-
ture.This publication is a continuation of authorsí
research dealing with analytical assessment of azole
antifungal drugs. Hitherto, analyses were performed
using such techniques as TLC (25) and GC (26) and
justified their usefulness in identification, separation
and quantitative determination of the investigated
compounds.
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Abstract: This paper presents a new methodology of quantitative determination of seven azole antifungal med-
icines widely used in therapy. Analyses were performed directly by using zero-order (fluconazole), first deriv-
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spectrophotometry. Validation of all methods confirms their proper precision (%RSD = 0.47 ñ 2.86), recovery
(98.7 ñ 101.4) and linearity (r coefficient over 0,999) in concentrations under investigation. The parameters
received enable the developed procedure to be used in quantitative and as auxiliary in qualitative pharmaceuti-
cal analysis.
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EXPERIMENTAL
Apparatus
Spectrophotometer UV-Vis Cary 100 Conc
(Varian Analytical Instruments, Palo Alto, USA)
was used for analysis. Scan speed was 3000 nm/min
and slit was 4 nm. Handling of results was enabled
by Cary WIN UV Conc software. Deuterium lamp
was a radiation source. Quartz cells of 10 mm width
were used.
Reference standards, reagents and investigated
preparations 
An analysis involved organic solutions with
concentration 4.8 µg mL-1 in case of bifonazole,
econazole i miconazole, 8.0 µg mL-1 for clotrima-
zole and 48.0 µg mL-1 in case of fluconazole, itra-
conazole and ketoconazole (standard solutions).
Itraconazole was dissolved in chloroform (1 : 4, v/v)
and filled up with methanol (3 : 4, v/v), whereas
other compounds were dissolved only in methanol. 
All reference standards were supplied by Sigma (St.
Louis, USA) and met the pharmacopoeia require-
ments. Two of the investigated substances: econa-
zole and miconazole, occurred in nitrate salt form
(pharmacopoeial form). Solutions were kept at low
temperature (4OC) and protected from light. Solvents
of analytical grade came from POCh (Gliwice,
Poland).
The analysis conditions established on refer-
ence standards were used for quantitative analysis of
selected analytes in medicinal products. The studies
were carried out on the preparation Fluconazole, 50
mg tablets (Polfarmex) and drug Ketokonazol, 200
mg tablets (Anpharm). The samples were prepared
by mixing a selected amount of average sample of
powdered tablets with methanol, shaking for 15 min
at frequency approx. 3 cycles/s and filtering through
filter paper No. 2. The prepared solutions had the
concentration of 48.0 µg ◊ mL-1 (sample solutions). 
Method parameters 
For solutions of reference standards and prepa-
rations with fluconazole and ketoconazole the UV
absorption spectra in range 200-400 nm were
obtained. The usefulness of zero-order spectropho-
tometry was verified with regard to quantitative
analysis. The results fulfilling accuracy requirement
were received for fluconazole (Figure 1), whereas
for ketoconazole interferences with matrix con-
stituents for zero-order and first derivative (D1)
spectra had negative influence on determination,
thus the second derivative (D2) was used (Figure 2).
For other compounds, for which there were no deter-
mination in medicinal products performed, method
validation was done for first derivative D1 (Figures
3 ñ 7). In case of drugs analyses ìbaseline-to-peakî
technique was used for determination. Analytical




Because of different shape of zero-order spec-
tra and specific λmax values, method enabled differ-
entiation of investigated medicines. The wave-
length, for which the maximum absorption occurred
equaled: bifonazole ñ 254 nm, clotrimazole ñ 205
nm, econazole nitrate ñ 204 nm with fold at 219 nm,
Figure 1. Zero-order spectra for fluconazole with signed analytical
wavelength λ = 261 nm.
Figure 2. Second order derivative spectra for ketoconazole with
signed analytical wavelength λ = 231 nm.
Determination of azole antifungal medicines... 21
fluconazole ñ 261 and 266 nm, itraconazole- 230
and 261 nm, ketoconazole 243 and 296 nm, and 204
nm in case of miconazole nitrate.
For each compound the value of molar absorptivi-
ty factor ε was established and the value of specific
absorptivity factor A1%1 cm was defined. These values,
determined at wavelength λmax, which are of importance
for qualitative analyses, are shown in Tables 1 ñ 3.
Method validation and quantitative analysis
After parameters of the method were estab-
lished, as described above, the method was validat-
ed. The validation (27) allowed precision, accuracy
and linearity (n=5) within the specified concentra-
tion range to be verified. Precision was measured in
the terms of repeatability of the series of obtained
results (n = 6) and was additionally checked inter-
day. Accuracy was determined as percentage recov-
ery (n=3) at three concentration levels (80, 100 and
120% addition of the reference standard). The limit
Figure 3. First order derivative spectra for bifonazole with signed
analytical wavelength λ = 241 nm. 
Figure 5. First order derivative spectra for econazole nitrate with
signed analytical wavelength λ = 232 nm.
Figure 4. First order derivative spectra for clotrimazole with
signed analytical wavelength λ = 209 nm.
Figure 6. First order derivative spectra for itraconazole with
signed analytical wavelength λ = 274 nm.
Figure 7. First order derivative spectra for miconazole nitrate with
signed analytical wavelength λ = 233 nm.
of detection (LOD) and limit of quantification
(LOQ) was found from ratio of the signal (S) to the
noise of the baseline (N) at the required ratio S/N for
LOD equal to 1:3, and 1:10 for LOQ.
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Under the established conditions the quantita-
tive determination of analyzed compounds was car-
ried out. For fluconazole and ketoconazole, deter-
minations were made in medicinal products in the
form of tablets of unmodified release (Table 1). For
these compounds the method selectivity was evalu-
ated by comparing the spectra shapes and λmax val-
ues for the analyzed product with those of the refer-
ece standard. No interferences at the analytical
wavelength with the preparation auxiliary sub-
stances were found. Fluconazole product included
lactose, maize starch, starch glyconate sodium salt,
polyvidon and magnesium stearate, whereas keto-
conazol preparation contained lactose, potato
Table 1. Method parameters for fluconazole and ketoconazole.
Fluconazole Ketoconazole
[50 mg/ tablet] [200 mg/ tablet]
Method zero-order second derivative
Analytical wavelength [nm] 261 231
Mean [mg/ tablet] 50.2 198.6
Precision [%RSD] 1.53 1.89
Recovery [%] 99.2 ÷ 101.4  98.7 ÷ 100.6
Linearity range [µg mL-1] 32.0 ñ 96.0 16.0 ñ 80.0 
Correlation coefficient (r) 0.9994 - 0.9993
LOD [µg mL-1] 5.0 0.6 
LOQ [µg mL-1] 24.0 2.1
ε [dm3 mol-1 cm-1] 1713.5 15758.6
A1%1 cm[100 mL cm-1 g-1] 55.9 296.5
Table 2. Method parameters for bifonazole and clotrimazole.
Bifonazole Clotrimazole
Analytical wavelength [nm] 241 209
Mean [D1 value] 0.0166 - 0.0522
Precision [%RSD] 1.17 1.92
Linearity range [µg mL-1] 1.6 ñ 8.0 4.8 ñ 11.2
Correlation coefficient (r) 0.9996 - 0.9992
LOD [µg mL-1] 0.3 2.0
LOQ [µg mL-1] 1.1 4.4
ε [dm3 mol-1 cm-1] 29077.4 50258.6
A1%1 cm[100 mL cm-1 g-1] 939.0 1457.5
Table 3. Method parameters for econazole nitrate, itraconazole and miconazole nitrate.
Econazole nitrate Itraconazole Miconazole nitrate
Analytical wavelength [nm] 232 274 233
Mean [D1 value] - 0.0331 - 0.0841 - 0,0308
Precision [%RSD] 2.81 0.47 2.86
Linearity range [µg mL-1] 1.6 ñ 8.0 16.0 ñ 80.0 1.6 ñ 8.0
Correlation coefficient (r) - 0.9998 - 0.9998 - 0.9999 
LOD [µg mL-1] 0.2 0.3 0.2 
LOQ [µg mL-1] 0.8 1.1 0.8
ε [dm3 mol-1 cm-1] 53412.7 31970.6 65565.2
A1%1 cm[100 mL cm-1 g-1] 1402.1 452.9 1570.8
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starch, microcrystalline cellulose, polyvidon, talc
and magnesium stearate as auxiliary substances.
Recovery for 80, 100 and 120% addition of the ref-
erence standard equal 99.7%, 99.2%, 101.4% for
fluconazole and 98.7%, 99.9%, 100.6% for keto-
conazole, respectively. 
Results of validation for bifonazole and clotri-
mazole are collected in Table 2, whereas parameters
for econazole nitrate, itraconazole and miconazole
nitrate are shown in Table 3.
The presented data on validation of determina-
tion method indicate proper parameters of the newly
developed procedure for all investigated com-
pounds, which enable making routine analysis in
medicinal products. 
DISCUSSION 
In order to perform quantitative determination
of investigated compounds, referential pharma-
copoeial monographs (European Pharmacopoeia 6,
Polish Pharmacopoeia VI, International Pharmaco-
poeia 4), for compounds under examination require
testing of reference standards per se by titration
method with potentiometric determination of the
end-point. However, this method is unsuitable for
analysis of these compounds in medicinal products
or biological material, where the presence of num-
ber of additional substances can affect the results of
determination. For analysis of such complex sam-
ples as drugs a selective method is required, e.g. the
spectrophotometric one. It should be noted that
monograph Ketoconazoli tabulettae from Polish
Pharmacopoeia VI (28) recommends testing the
tablets with ketoconazole using spectrophotometric
method, but only with regard to prove the active
substance identity. 
Quantitative analysis in medicinal products
performed basing on zero-order spectra often do not
fulfilled the accuracy requirement because of inter-
ferences with auxiliary substances from sample
matrix. By derivatization of zero-order spectra,
derivative spectra are received for which determina-
tion results are usually characterized by a smaller
error. Derivative spectrophotometry technique is
more selective and sensitive enabling more accurate
analyses (29).
Hitherto, research in azole antifungal medi-
cines group using UV spectrophotometric tech-
nique, do not covered itraconazole determination. In
this paper conditions and results of its analysis is
shown for the first time. Compounds were dissolved
in methanol (itraconazole in chloroform and
methanol), what should be considered as a method
attitude ñ methanol is the most common and well
available solvent.
Unfortunately, UV spectrophotometric tech-
nique cannot be used for unequivocal qualitative
analysis. Qualitative determination was elaborated
by authors using chromatographic methods; TLC
(25) and GC (26). Moreover, chromatographic tech-
niques enabled separation of compounds under
investigation, what was not possible using only UV
spectroscopy. TLC-densitometric procedure was the
best for purity examination, whereas GC method
enabled determination of the smallest quantities of
medicines.
CONCLUSION
A new analytical procedure for direct deter-
mination of seven common azole medicines using
UV spectrophotometry was evaluated. Essential
parameters which are of importance for qualitative
analyses were established. The method of quantita-
tive analysis of bifonazole, clotrimazole, econa-
zole, fluconazole, itraconazole, ketoconazole and
miconazole is suitable for routine determination of
these compounds. Validation parameters are prop-
er and proves methodís usefulness for intended
purpose of pharmaceutical analysis. Probably, this
methodology can be also applied to analyze the
above mentioned compounds in biological and
environmental materials after appropriate prelimi-
nary preparation.
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